

Supplemental Material (Online only)

A Pooled Analysis of Fall Incidence From Placebo-controlled Trials of Denosumab

Pojchong Chotiyarnwong MD PhD,^{1,2*} Eugene McCloskey MD,^{2*} Richard Eastell MD,²

Michael McClung MD,³ Evelien Gielen MD PhD,⁴ John Gostage MRes,² Michele

McDermott MD,⁵ Arkadi Chines MD,⁵ Shuang Huang PhD,⁵ Steven R. Cummings MD⁶

*Co-first authors.

¹Department of Orthopaedic Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand

²Academic Unit of Bone Metabolism, Department of Oncology and Metabolism, The Mellanby Centre For Bone Research, The Centre for Integrated Research in Musculoskeletal Ageing, University of Sheffield, Sheffield, UK

³Oregon Osteoporosis Center, Portland, OR, USA

⁴Center for Metabolic Bone Diseases, University Hospitals Leuven, Leuven, Belgium and Department of Chronic Diseases, Metabolism and Aging (CHROMETA), KU Leuven, Leuven, Belgium

⁵Amgen Inc., Thousand Oaks, CA, USA

⁶San Francisco Coordinating Center, California Pacific Medical Center (CPMC) Research Institute and the University of California, San Francisco, CA, USA

Correspondence

Prof. Eugene McCloskey
Academic Unit of Bone Metabolism
Metabolic Bone Centre
Northern General Hospital
Herries Rd
Sheffield S5 7AU
United Kingdom
Tel: +44 114 2159694
Email: e.v.mccloskey@sheffield.ac.uk

Supplementary Figure S1 Impact of denosumab on falls risk (defined as one fall or more during follow-up) compared to the placebo arm, expressed as hazard ratio, across the range of age at baseline.

